939-23-1|4-Phenylpyridine| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 939-23-1 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Citations

4H-Dewar Pyridines: Dearomative approach towards programmable piperidine isosteres

Jan Petrovčič ;

Abstract: Piperidine is the most frequently encountered aliphatic heterocycle in medicinal chemistry. Despite its prevalence, there is a constant demand for improvement of ADME (absorption, distribution, metabolism, excretion) properties of piperidine-containing drugs and drug candidates. 2-azabicyclo[2.2.0]hexanes present an exciting class of more rigid and structurally programmable piperidine isosteres. EVA (exit vector analysis) of the most frequently employed piperidine isosteres and 2-azabicyclo[2.2.0]hexanes is presented, and a side-by-side comparison is made. This dissertation describes our endeavors towards the expansion of accessible 2-azabicyclo[2.2.0]hex-5-ene chemical space, our exploration of 2-azabicyclo[2.2.0]hex-5-ene scaffold reactivity in olefin functionalization reactions and installation of synthetically useful handles. The malleability and practicality of 2-azabicyclo[2.2.0]hexane core is demonstrated by preparation of several isosteres of piperidine-containing drugs and lead compounds. A general blueprint for functionalized 2-azabicyclo[2.2.0]hexanes is devised. Special attention is devoted to “pseudoaxial” C5-substituted-2-azabicyclo[2.2.0]hexanes, which could serve as isosteres of piperidines in their thermodynamically unfavorable axial conformations without the need to introduce additional carbon atoms. La piperidina è l’eterociclo alifatico più frequente nella chimica farmaceutica (medicinal chemistry). Nonostante la sua prevalenza, c’è una costante domanda for il miglioramento delle proprietà ADME (assorbimento, distribuzione, metabolismo, escrezione) di farmaci e candidati farmaci contenenti strutture piperidiniche. Gli 2-azabiciclo[2.2.0]esani rappresentano un’interessante classe di isosteri della piperidina più rigidi e programmabili strutturalmente. L’EVA (exit vector analysis, analisi di vettore di uscita) degli isosteri della piperidina più frequentemente utilizzati e di 2-azabiciclo[2.2.0]esani viene mostrata, ed è stata eseguita una comparazione tra loro. Questa tesi descrive i nostri sforzi verso l’espansione di spazio chimico accessibile dei 2-azabiciclo[2.2.0]es-2-eni, la nostra esplorazione della reattività della struttura di tipo 2-azabiciclo[2.2.0]es-2-ene nelle reazioni di funzionalizzazione delle olefine e l’installazione di appigli sinteticamente utili. La malleabilità e praticabilità del nucleo di tipo 2-azabiciclo[2.2.0]es-2-ene è dimostrata dalla preparazione di diversi isosteri di farmaci e composti guida, contenenti strutture piperidiniche. Un progetto generale per la funzionalizzazione di 2-azabiciclo[2.2.0]es-2-eni è stato elaborato. Un’attenzione particolare è stata riservata ai 2-azabiciclo[2.2.0]es-2-eni con sostituenti sul C5 “psuedoassiali”, che possono servire come isosteri di piperidine nella loro conformazione assiale termodinamicamente sfavorevole, senza la necessità di introdurre atomi di carbonio addizionali.

Purchased from AmBeed: 100-54-9 ; 939-23-1 ; 3796-23-4 ; 3430-16-8 ; 154105-64-3

Product Details of [ 939-23-1 ]

CAS No. :	939-23-1
Formula :	C₁₁H₉N
M.W :	155.20
SMILES Code :	C1(C2=CC=CC=C2)=CC=NC=C1
MDL No. :	MFCD00006420
InChI Key :	JVZRCNQLWOELDU-UHFFFAOYSA-N
Pubchem ID :	13651

Safety of [ 939-23-1 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335-H413
Precautionary Statements:	P261-P264-P271-P273-P280-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P403+P233-P405-P501

Computational Chemistry of [ 939-23-1 ] Show Less

Physicochemical Properties

Num. heavy atoms	12
Num. arom. heavy atoms	12
Fraction Csp3	0.0
Num. rotatable bonds	1
Num. H-bond acceptors	1.0
Num. H-bond donors	0.0
Molar Refractivity	49.67
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	12.89 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.09
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.59
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.75
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.13
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.09
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.53

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.11
Solubility	0.121 mg/ml ; 0.00078 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.51
Solubility	0.48 mg/ml ; 0.00309 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-4.53
Solubility	0.00462 mg/ml ; 0.0000298 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.41 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	2.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.11

Application In Synthesis of [ 939-23-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 939-23-1 ]

[ 939-23-1 ] Synthesis Path-Downstream 1~11

1
[ 1131-61-9 ]
[ 109-89-7 ]
[ 939-23-1 ]
[ 19006-81-6 ]
[ 118158-22-8 ]
[ 118158-21-7 ]

References: [1]Heterocycles,1988,vol. 27,p. 113 - 124.

2
[ 1131-61-9 ]
[ 939-23-1 ]
[ 19006-81-6 ]
[ 118158-22-8 ]
[ 118158-21-7 ]

References: [1]Heterocycles,1988,vol. 27,p. 113 - 124.

3
[ 939-23-1 ]
[ 54151-74-5 ]

Yield	Reaction Conditions	Operation in experiment
55.1%		Dimethylaminoethanol (DMAE, 1.50 mL, 15.0 mmol) was dissolved in hexane (20.0 mL) stirred at ice-cooling. A small amount of n-butyllithium (2.5 mol / L hexane solution, 12.0 mL, 30.0 mmol) was successively dropped under ice-cooling, and the mixture was stirred for 30 minutes. A small amount of 4-phenylpyridine (776 mg, 5.00 mmol) in hexane (30.0 mL) was added dropwise under ice-cooling, and the mixture was stirred for 1 hour in this state.After the reaction solution was cooled to -78 C, a small amount of the solution (15.0 mL) of carbon tetrafromide (6.30 g, 18.0 mmol) was successively dropped, and the mixture was stirred for 50 minutes. The purified water was added under ice cooling to stop the reaction, followed by extraction with ethyl acetate (100 mL × 2). The organic layer was washed with saturated brine, then dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography using ethyl acetate / hexane (1/4 (volume ratio)) as an elution solvent to obtain Compound 7 in a yield of 645 mg (yield 55.1%).

References: [1]Journal of Organic Chemistry,2003,vol. 68,p. 2028 - 2029.
[2]Patent: TW2016/39840,2016,A .Location in patent: Paragraph 0020; 0040.
[3]Patent: WO2007/20888,2007,A1 .Location in patent: Page/Page column 43.
[4]Journal of the American Chemical Society,1956,vol. 78,p. 5842.

4
[ 939-23-1 ]
[ 39795-60-3 ]

Yield	Reaction Conditions	Operation in experiment
14%	With bromine;aluminium trichloride; In nitrobenzene;	EXAMPLE I A mixture of one molar proportion of 4-phenylpyridine and 1.2 molar proportions of anhydrous aluminum chloride in 4.9 molar proportions of nitrobenzene was stirred at 85°-95° C. in nitrogen atmosphere to form a gray solution to which 1.2 molar proportions of bromine were added over a period of 30 minutes. The resultant solution was stirred at 85°-95° C. overnight and then poured onto cracked ice. The reaction was worked-up using conventional acidbase partitioning to give the bromide as a semi-solid mass. Gas chromatographic analysis using biphenyl as an internal standard showed that 89percent of the 4-phenyl pyridine was reacted to give a 32percent yield of 4-(4-bromophenyl)pyridine, a 35percent of 4-(3-bromophenyl)pyridine, a 15percent yield of 4-(2-bromophenyl)pyridine, and a 14percent yield of dibromides. Recrystallization of the mass from n-hexane gave 4-(4-bromophenyl)pyridine as beautiful white needles, m.p. 127-9; pure by gc and nmr analyses.

References: [1]Patent: US4554352,1985,A .

5
[ 109-99-9 ]
[ 939-23-1 ]
[ 130-85-8 ]
C₂₃H₁₆O₆*2C₁₁H₉N*C₄H₈O [ No CAS ]